Blog

  • Expanded vaccine screening in emergency departments could benefit underserved populations

    Expanded vaccine screening in emergency departments could benefit underserved populations

    About 49% of people are unaware of one or more vaccines recommended for them. Further, 86% have not received one or more of these vaccines.

    These are the findings of a University of California, Riverside-led study published today in Morbidity and Mortality Weekly Reports. The study is the first national comprehensive vaccine surveillance study conducted in emergency departments, or EDs – the only health care access point for millions of underserved Americans.

    Vaccination screening is one of the most fundamental public health interventions. Vaccines – along with water sanitation – have saved more lives than any other public health intervention. But nearly a third of the U.S. population lacks primary care access and rarely receives this screening.”


    Dr. Robert Rodriguez, professor of medicine and associate dean of clinical and population health research at the UC Riverside School of Medicine and lead author of the study

    From April through December 2024, the investigators conducted a survey study of 3,285 non-critically ill adult patients – people visiting the ED for reasons like minor injuries or illnesses – in 10 emergency departments in eight U.S. cities. 

    “We found lack of vaccination was more common among African Americans, uninsured individuals, and those without a primary care provider,” Rodriguez said. 

    In the survey, the patients were asked age-specific questions about 6–10 recommended vaccines, including shingles, pneumococcal, RSV, tetanus, COVID-19, and influenza. For each vaccine that was recommended for them, the researchers asked if the patients had heard of it, whether they had received it, and if not, why. They also asked the patients if they would accept the vaccine if it was offered to them in the ED.

    “Roughly 50% of unvaccinated participants said they would accept vaccines if offered during their ED visit,” Rodriguez said. 

    According to him, traditional vaccine survey methods like the National Health Interview Survey miss many groups because they rely on home visits or phone calls, which exclude people who are unhoused or unlisted.

    “Our analysis suggests that if vaccine screening and delivery programs were implemented widely in EDs, the rate of adult ED patients who are fully up-to-date on their vaccines could increase from its current level of 14% to as high as 48% – more than tripling the current rate,” he said. “As the only health care access point for underserved populations, EDs can fill this fundamental public health services gap. This could be a game changer for vaccine equity.”

    Rodriguez explained that vaccine screening is typically done by primary care providers, who ask patients about their vaccination history and recommend any needed vaccines. 

    “But about 30% of the U.S. population doesn’t have a primary care provider and relies exclusively on EDs for healthcare,” he said. “This group includes people without insurance, many homeless individuals, and immigrants – people who often fall through the cracks in traditional healthcare systems.”

    To close this critical gap in health services, Rodriguez and his colleagues call for collaborations between public health officials and ED personnel to create effective programs for vaccine screening, outreach, and delivery aimed at underserved communities. 

    “We propose expanding vaccination efforts within EDs by implementing comprehensive screening initiatives, which could substantially boost immunization rates and help address existing health inequities,” Rodriguez said. “Because many vaccines may not be available in EDs, the vaccination delivery programs should include referrals to pharmacies, clinics, and other sites that can administer vaccines.”

    Next, the researchers will explore ways to automate the vaccination screening process, making it less labor-intensive. “We’re also exploring mobile outreach options for those who cannot make it to EDs,” Rodriguez said.

    Rodriguez was joined in the study by colleagues at UCLA, UC San Francisco, Thomas Jefferson University in Pennsylvania, Wayne State University in Michigan, Rush University Medical Center in Illinois, and Duke University in North Carolina.

    The study was supported in part by a grant from the National Institute of Allergy and Infectious Diseases.

    The title of the paper is “An Emergency Department-Based Vaccine Surveillance Study of Underserved Populations – eight U.S. cities, April–December 2024.”

    Source:

    University of California – Riverside

    Journal reference:

    Rodriguez, R. M., et al. (2025) Emergency Department Survey of Vaccination Knowledge, Vaccination Coverage, and Willingness to Receive Vaccines in an Emergency Department Among Underserved Populations — Eight U.S. Cities, April–December, 2024. MMWR Morbidity and Mortality Weekly Reports. http://dx.doi.org/10.15585/mmwr.mm7429a1.

    Continue Reading

  • US Stroke Rehab System Not Serving Patient Needs, Societies Say

    US Stroke Rehab System Not Serving Patient Needs, Societies Say

    Access to rehabilitation is a “lifeline” for patients that needs to be protected and preserved to ensure their recovery.

    A patient’s ability to obtain timely and adequate access to rehabilitation services after a stroke is often dictated by racial, ethnic, socioeconomic, and geographic issues rather than their own needs, according to a joint policy statement from the American Heart Association (AHA) and the American Stroke Association (ASA).

    Committee chair Nneka L. Ifejika, MD, MPH (University of Texas Southwestern Medical Center, Dallas), noted to TCTMD that the majority of the committee members who authored the statement are active practitioners of stroke rehabilitation and recovery who have become increasingly concerned about the widening gaps they see in access to postacute care (PAC) services. The policy statement represents the first time the AHA and ASA have taken an advocacy approach to address these issues.

    “Ideally, stroke rehabilitation starts in the hospital and there’s a good continuity of care to the postacute realm,” Ifejika added. Whether the patient transitions to inpatient rehab, a skilled nursing facility, an outpatient rehab center, or even telerehabilitation, the committee says there’s no standardized framework in place to ensure equitable continuity of care after a stroke.

    In the policy statement published recently in Stroke, Ifejika and colleagues pinpoint some of the major gaps and issue a call for action to preserve and improve access to stroke rehab, which they term “a lifeline of hope” not just for patients, but also for their families, caregivers, and communities.

    “We’ve made all these wonderful strides in acute stroke treatment, but we’re not making similar strides in stroke rehabilitation and recovery,” Ifejika said.

    Unlike cardiac rehab, which is focused on helping the patient improve functional endurance after an acute cardiac event, stroke rehab can be directed at more subtle issues that nevertheless interfere with patients getting back to daily routines like self-care and work and regaining their sense of independence and identity.

    “Patients may have cognitive impairments, they may have sensory impairments, they may have motor impairments,” Ifejika noted. “They may have difficulty with depression or anxiety, and so it’s a more of a multifactorial rehabilitation that we’re addressing after a stroke.”

    Payers, Unmet Needs, and Advocacy

    In looking at what’s driving the types of poststroke care that patients receive, the committee notes that among other things, partnerships among health corporations, hospitals, health systems, and physician groups can have a big impact.

    “Such partnerships can result in a conflict of financial interest between the needs of these organizations and the patient’s clinical needs,” they write. “In some areas of the United States, the reach of large healthcare systems or conglomerates limits access to PAC options.” They also cite a lack of transparency regarding the factors used to make determinations on behalf of patients about their options.

    According to Ifejika and colleagues, a congressional subcommittee recently investigated three Medicare Advantage programs that they say disproportionately select against patients having access to PAC.

    The US Senate Permanent Subcommittee on Investigations detailed in a 2024 report how all three programs—UnitedHealthcare, Humana, and CVS—use artificial intelligence (AI), predictive models, and automation to deny access to PAC. Using these methods, the subcommittee said, Humana’s denial rate for long-term acute hospitals increased by 54% between 2020 and 2022, UnitedHealthcare’s prior authorization denial rate for PAC increased from 10.9% in 2020 to 22.7% in 2022, and CVS admitted to saving $660 million in 2018 by denying prior authorizations submitted for Medicare Advantage beneficiaries for inpatient PAC.

    Patients tend to get lost to follow-up because they look normal, when in fact they aren’t. Nneka L. Ifejika

    Delving into unmet needs, the new document’s committee says stroke survivors and their families need more thorough education during the acute hospitalization about all PAC options and should be provided with consistent follow-up at 30 and 90 days that includes documentation of modified Rankin Scale score. In addition to addressing the needs of the patient, PAC can also help family members who are becoming first-time caregivers to understand a host of things they will need to do, from assisting in activities of daily living to preventing falls.

    Throughout the policy statement, Ifejika and colleagues note the importance of advocacy to improve the stroke rehabilitation system and give patients and caregivers information they need to make informed decisions. That includes developing performance measures as well as public policy guidance to ensure that the PAC matches the needs of all patients, including those who are under- or uninsured so could get lost to care and follow-up once they leave the hospital.

    Among the priorities that the committee sees as being crucial going forward are:

    • More resources for the study of stroke rehab with research questions that directly reflect practical, day-to-day challenges of clinicians, families, and patients
    • An open-access surveillance system for collecting data across the full spectrum of stroke type, severity, demographics, health systems, hospitals, and payers
    • Better understanding of how variability in rehab care is influenced by health systems, hospitals, insurance, and alternative payment models
    • A comprehensive inventory of coverage policies of all major payers/insurers in the US and field surveys of discharge planners at acute hospitals to uncover barriers to PAC recommendations
    • Comparative effectiveness and cost-effectiveness studies of different rehabilitation strategies
    • Expansion of clinical training programs to improve understanding of patient, family, and caregiver needs after discharge, including the role of social determinants of health as they relate to medical care and access to community resources for PAC
    • More research into the transition from hospital to home

    Importantly, Ifejika said, there is still much to be learned not only about which services patients need after a stroke, but when they need them, because each recovery is different and may not be linear.

    “There has to be an understanding that when they’re in the hospital, they may present as having no additional neurologic deficits, or they may present as being normal. You haven’t seen them out in the community yet, so you really don’t know whether they have additional impairments,” she said. “Patients tend to get lost to follow-up because they look normal, when in fact they aren’t. Unfortunately, that contributes to increased costs because they [may not be] able to go back to work . . . or someone has to stay home or a caregiver has to be hired.”


    Continue Reading

  • Hot Hot Deal: Save 42% on This Sleek Samsung Tablet at Walmart – PCMag

    1. Hot Hot Deal: Save 42% on This Sleek Samsung Tablet at Walmart  PCMag
    2. The best budget tablet of 2025 just slashed another $64 off the price tag  Android Police
    3. It’s not all that often you can get one of our favorite Samsung tablets for 30% off, so don’t miss out  Android Central
    4. Best tablet deals for August 2025, from Samsung, Amazon and more  MSN
    5. Samsung’s Galaxy Tab S6 Lite Is Now Just $210 on Amazon, and Shoppers Say It’s ‘the Best Tablet’ Out There  Men’s Journal

    Continue Reading

  • Microsoft Adds New OpenAI Models to Azure and Windows

    Microsoft Adds New OpenAI Models to Azure and Windows

    Microsoft is expanding its AI tools by bringing OpenAI’s open-weight language models, gpt-oss, to Azure AI Foundry and Windows AI Foundry. Two of these models debuted this week: gpt‑oss-120b and gpt‑oss-20b. The larger 120b model is built for high-performance reasoning tasks, while the smaller 20b model works on PCs with GPUs that have at least 16GB of memory.

    Developers have full access to the model weights, which means they can fine-tune the models to suit different needs. That could mean trimming for offline use or modifying them for industry-specific assistants. Open-weight access lets teams review models, retrain parts of them, or export them for use on Microsoft’s AKS or local computers.

    Azure AI Foundry offers support via tools for model evaluation, fine-tuning, and deployment. It includes a growing catalog of more than 11,000 models. Meanwhile, Foundry Local offers on-device support, which can help those who require local inference for security or offline access.

    OpenAI’s gpt‑oss-20b is already available on Windows, with macOS support slated for the near future. Both models will be compatible with the common responses API.

    Microsoft says its approach is meant to give developers and businesses more flexibility, transparency, and options for how they use and manage AI across different environments, whether in the cloud, on-device, or at the edge.

    Continue Reading

  • How & Where To Watch Al Nassr Vs Rio Ave F.C? Start Time, Live Streaming Online & TV Channels For Pre-Season Friendly – Athlon Sports

    1. How & Where To Watch Al Nassr Vs Rio Ave F.C? Start Time, Live Streaming Online & TV Channels For Pre-Season Friendly  Athlon Sports
    2. [.FREE-TV.]**Al-Nassr vs Rio Ave LIVE STREAMS Friendly TV CHANNEL 2025  OrilliaMatters.com
    3. Cristiano Ronaldo arrives in Lagos with Al-Nassr squad for pre-season  GhanaWeb
    4. Ronaldo, Al-Nassr teammates arrive in Lagos for preseason  Daily Post Nigeria
    5. Lagos goes wild as Cristiano Ronaldo arrives with Al Nassr for pre- season tour  PM News Nigeria

    Continue Reading

  • Who’s a good robot dog? Bert and Spot explore Mars-like surface with help from AI and astronaut in space

    Who’s a good robot dog? Bert and Spot explore Mars-like surface with help from AI and astronaut in space

    Two four-legged robots recently explored a practice Mars yard, with a little help from an astronaut in space and several robot buddies.

    The robot team, along with the “Neal AI” chatbot and NASA astronaut Jonny Kim, worked together on tough tasks in a German site meant to simulate Mars terrain.

    Continue Reading

  • Unprecedented large-scale aquifer recovery through human intervention

    Unprecedented large-scale aquifer recovery through human intervention

    Reversing groundwater depletion across the North China Plain

    To investigate groundwater recovery in the NCP, we compiled an extensive dataset of in-situ groundwater level measurements from both unconfined and confined aquifers in urban and rural areas within the NCP. The establishment of China’s national groundwater monitoring project in 2018 markedly improved the spatiotemporal coverage and quality of in situ measurements. Prior to 2018, there were many temporal discontinuities in the monitoring data, but the advent of an automatic monitoring system thereafter provided continuous data. Post-2018, there was a notable increase in monitoring well density in the NCP, particularly in the southeastern portions and in confined aquifers (Supplementary Fig. 1). For unconfined aquifers, groundwater levels were deepest (≥40 m) in the piedmont plain in the western portion of the NCP and shallowest (≤10 m) in the eastern portion of the NCP (Supplementary Fig. 1a–d). For confined aquifers, groundwater heads were deepest (≥70 m) in the cities of Tianjin, Cangzhou, and Hengshui (Supplementary Fig. 1e–h). Rapid shallowing trends have been observed across the NCP in both unconfined and confined aquifers (Fig. 2). We calculated Theil-Sen slopes for depth to groundwater at monitoring wells during 2020–2024 (Fig. 2m) because 2020 marked the point of reversal in the average groundwater depth in the NCP. In unconfined aquifers, the most pronounced reversal in groundwater levels was found in the piedmont plain in the western portion of the NCP, with trends exceeding 1.5 m year1 during 2020–2024. In confined aquifers, rapid shallowing trends in groundwater heads (≥1.5 m year1) were evident in the piedmont areas, as well as in the cities of Tianjin, Cangzhou, and Hengshui. Additionally, wells with continuous measurements indicated recovery in both urban and rural areas (Fig. 2b–l).

    Fig. 2: Trends in groundwater depths across monitoring wells in the North China Plain and comparisons with previously reported cases of recovery.

    a Overview of the Hai River basin (HRB). The purple line represents the boundary of the HRB. The green line represents the northern and western boundary of the North China Plain (NCP), which is the plain portion of the HRB. Orange lines represent the central route of the South-to-North Water Diversion (SNWD-C). Blue polygons represent reservoirs. Brown lines represent the boundaries of Hebei Province and the provincial-level municipalities of Beijing and Tianjin (Province). Red diamonds represent major cities. Purple circles represent the locations of monitoring wells (bl). bj Instances of continuous depth to groundwater measurements in unconfined aquifers during 2005–2024. Green lines represent the depth to groundwater. Thick blue lines illustrate the long-term trends derived from STL decomposition. k, l Instances of continuous depth to groundwater measurements in confined aquifers during 2005–2024. Purple lines represent the depth to groundwater. Thick red lines illustrate the long-term trends derived from STL decomposition. m Trends in groundwater levels and heads at individual wells during 2020–2024. Circles indicate unconfined aquifers, while Deltas represent confined aquifers. Positive trends (blue) indicate shallowing groundwater, while negative trends (red) indicate deepening groundwater.

    The groundwater level data indicate that the reversal of deepening trends in the average groundwater depth anomalies in both unconfined and confined aquifers occurred around 2020 (Fig. 3a). By the end of 2024, the average groundwater depth was ~11 m and ~27 m in unconfined and confined aquifers, respectively. In general, depths to groundwater in unconfined and confined aquifers are greatest in summer and smallest in winter, driven primarily by the combined effects of groundwater pumping for irrigation (peaking in spring) and recharge from precipitation (summer monsoonal rainfall accounting for ~60% of annual precipitation). Seasonal variability in groundwater depth within a year is ~1.5 m in unconfined aquifers and ~4 m in confined aquifers. To mitigate the impact of seasonal variability, we isolated the long-term trends in the groundwater depth anomaly time series after removing the seasonal variability using STL decomposition. Our analysis shows that the rate of deepening in groundwater depth in unconfined aquifers slowed before the reversal in 2020 compared to the deepening trend in the late 20th century. Historically, groundwater levels in unconfined aquifers in the Piedmont Plain declined at a rate of 1–2 m year1 during 1984–200524. The deepening trend decreased to 0.2 m year1 during 2005–2019, with relatively humid conditions in 2012 and 2016 contributing to mild recoveries. After the reversal in 2020, a rapid recovery rate of 0.7 m year1 occurred during 2020–2024, with the average groundwater depth anomaly in unconfined aquifers in 2024 nearing levels last seen in 2005. For confined aquifers, we found a deepening trend of ~0.5 m year1 during 2005–2019, followed by a recovery of ~4 m during 2020–2024. By 2024, the average groundwater head had returned to levels comparable to those in 2013. Notably, the recovery rates for both unconfined and confined aquifers decreased after 2021. Additionally, numerous sources have indicated a recovery in groundwater levels, as shown by the mitigation of land subsidence and re-emergence of springs in regions such as Beijing and Xingtai (see Methods).

    Fig. 3: Time series and trends in groundwater depths across the North China Plain.
    figure 3

    a Time series of average groundwater level anomalies in unconfined and average groundwater head anomalies in confined aquifers. The green and purple lines represent the average groundwater level and head anomalies in unconfined and confined aquifers, respectively. The thick blue and red lines illustrate long-term trends in unconfined and confined aquifers derived from STL decomposition, respectively. The green and purple shadows represent the uncertainty associated with the spatial distribution of the monitoring network and the application of the Thiessen polygon method in unconfined and confined aquifers, respectively. The dashed brown lines represent the timing of reversals. b Average groundwater level anomalies in unconfined aquifers at the city scale. Same legend as in (a). c Proportion of monitoring wells exhibiting deepening (p < 0.05, red), shallowing (p < 0.05, light blue), reversing (dark blue), and no significant trend (orange) during 2005–2017 and 2018–2024.

    Beijing experienced the first reversal of deepening groundwater levels in unconfined aquifers, followed by other cities in the NCP (Fig. 3b). Monitoring data from Beijing, the city with the highest quality data in the NCP, indicated the earliest reversal in 2016, followed by a recovery rate of 1 m year1 during 2016–2024. Since 2021, Beijing’s groundwater level has been shallower than it was in 2005. In Baoding, the reversal occurred in 2020, with a recovery rate of 1.5 m year1 during 2020–2024. By 2024, the groundwater level in Baoding was shallower than in 2005. The recovery of groundwater levels in Hengshui and Tangshan has been ongoing since 2021, albeit at a slower rate of 0.4 m year1 and 0.3 m year1, respectively. The lower uncertainty in average groundwater depth anomalies for Beijing and the NCP, compared to Baoding, Hengshui, and Tangshan, underscores the importance of dense in-situ monitoring networks and comprehensive regional analysis in improving the reliability of groundwater assessments.

    We identified and analyzed trends in groundwater depth at continuously monitored wells during 2005–2017 and 2018–2024 (Fig. 3c). A well displaying a monotonic deepening trend followed by a monotonic rebound was labelled as having a reversal of the deepening trend. For other wells, we assessed whether there was a significant deepening or shallowing trend (p < 0.05, MK test). Our findings show that significant deepening trends were predominant during 2005–2017, whereas significant shallowing trends became prevalent during 2018–2024. Approximately 62% and 83% of the monitoring wells in unconfined and confined aquifers show significant deepening trends during 2005–2017, respectively. Approximately 6% of the monitoring wells in unconfined aquifers, mainly in Beijing, experienced a reversal of the deepening trend during this period. In contrast, during 2018–2024, over half of the monitoring wells exhibited a significant shallowing trend, and about a quarter showed signs of a deepening trend reversal. These results align with the first reversal observed in Beijing in 2016 and the overall reversal at the NCP scale in 2020.

    Water supply and usage in the Hai River basin

    The total water supply in the HRB has remained relatively stable from 2005 to 2023, averaging ~37 km3 annually, but the contribution of different water sources has shifted significantly (Fig. 4a, b). In 2005, groundwater accounted for about two-thirds of the total water supply, with unconfined aquifers providing 18.7 km3, nearly three times the 6.6 km3 supplied by confined aquifers. Around 2009, groundwater extraction from confined aquifers began to decline, providing 5% less in 2014 relative to the volume provided in 2005, with reclaimed water compensating for most of this reduction. Meanwhile, surface water supply from reservoirs increased (+1.8 km3) during 2005–2023 and now constitutes over a quarter of the total water supply. Water diverted from the Yellow River remained stable at ~4.4 km3 annually, representing 10% of the total water supply, except for a spike in 2019 and 2020. Reclaimed water use grew steadily, reaching 4.4 km3 by 2023 and accounting for 12% of the total water supply in 2023. Reclaimed water is primarily used for river and lake replenishment, as well as for sanitation, landscape irrigation, and industry. Despite initiatives promoting desalination, the use of desalinated seawater in the HRB has remained minimal, with an annual capacity of ~0.25 km3 in 2023, contributing <1% to the total water supply.

    Fig. 4: Annual water supply and usage in the Hai River basin.
    figure 4

    a Annual water supply from various sources (km3), including surface water from reservoirs, groundwater from unconfined and confined aquifers, water diversion from the Yellow River, water diversion from the Yangtze River (South-to-North Water Diversion, SNWD), and reclaimed water. b Proportions of total water supply in 2005, 2014, and 2023. c Annual water use across different sectors (km3), including municipal, agricultural, industrial, and environmental water usage. d Proportions of total water use in 2005, 2014, and 2023.

    The central route of the South-to-North Water Diversion (SNWD-C), which began operations in December 2014, introduced significant diversification into the water supply structure of the HRB. The SNWD-C was designed to divert 9.5 km3 of high-quality water annually from the Danjiangkou Reservoir on the Han River, the largest tributary of the Yangtze River, to northern China. The eastern route of the SNWD (SNWD-E), which diverts water from Jiangdu near the Yangtze River, supplies a small amount of water (~0.2 km3 year1) to the southeastern parts of the NCP, with the majority benefiting areas in Shandong Province outside the NCP. In 2023, the SNWD provided 5.3 km3 of water, accounting for 14% of the total supply, making it the third largest source after unconfined aquifers (11.9 km3, 32%) and surface water from reservoirs (10.4 km3, 28%).

    Groundwater usage in 2023 (~13 km3) was nearly half of what it was in 2005 (~25 km3), with a steeper decline in confined aquifers (~85% reduction) than in unconfined aquifers (~36% reduction) from 2005 to 2023. By 2023, pumping from confined aquifers decreased to <1 km3, accounting for only 3% of the total water supply. This greater reduction in confined aquifer use is largely attributed to its greater substitution by water from the SNWD project. Historically, confined aquifers, valued for their high water quality, have been a primary source for municipal use, particularly because unconfined aquifers are more vulnerable to contamination. With the introduction of water from the SNWD project, groundwater from confined aquifers that had been used for municipal supplies has increasingly been replaced, thereby reducing groundwater pumping. However, the SNWD supply is affected by drought conditions in its source areas. For example, drought conditions upstream of the Danjiangkou Reservoir led to the SNWD supply being decreased by 16% from 2022 to 2023 (from 6.3 km3 to 5.3 km3).

    Despite generally stable total water use, a shift towards increased allocation to environmental flows has led to a reduction in total municipal, agricultural, and industrial use, from 37.6 km3 in 2005 to 29.5 km3 in 2023 (Fig. 4c, d). Agricultural water use, which accounted for 70% of the total in 2005, has steadily declined to 50% by 2023. In addition to a ~ 10% decrease in cropland area (Supplementary Fig. 2), this reduction is attributed to policies aimed at mitigating water shortages and curbing groundwater extraction, including adjustments to cultivation practices, dryland farming, seasonal fallow, and use of plastic mulch to conserve soil moisture30. Municipal water use increased by ~30% during 2005–2023, driven by population growth, while industrial water use decreased by a similar percentage due to conservation efforts31. Environmental water use, which includes watering trees and grasslands as well as replenishing lakes and rivers17, has been over 7 km3 since 2021, becoming the second-largest water use sector (>20% of the total) after agriculture. Reclaimed water, along with water diverted from the Yellow and Yangtze rivers and surface water from reservoirs32, plays a crucial role in supporting these environmental flows17.

    Water diversion and aquifer restoration policies drive groundwater recovery

    The observed groundwater recovery in the NCP is primarily attributable to sustained human intervention, with wet years (e.g., 2021) providing additional but temporary reinforcement (Fig. 5). A pivotal measure was the substitution of groundwater pumping with water from SNWD-C. Initially, in 2015, Beijing received the bulk of diverted water (0.8 km3 out of 1.4 km3 delivered to the NCP), which led to an early recovery of groundwater levels beginning in 2016. This recovery remained resilient even during droughts in 2019 and 2022 (Fig. 5c). After 2020, SNWD-C deliveries expanded to other parts of the NCP, reaching over 4 km3 per year and supporting a broader reversal of regional groundwater declines (Fig. 5a).

    Fig. 5: Groundwater depth response in unconfined aquifers to precipitation variability.
    figure 5

    a Annual precipitation in the Hai River basin (HRB, white bars) and average groundwater depth anomalies in unconfined aquifers across the North China Plain (NCP). Background shading denotes dry (orange), normal (gray), and wet (blue) years. The red line shows the long-term trend in average groundwater depth anomalies, derived via STL decomposition. b Scatter plot relating 12-month average precipitation (Pr) in the HRB to the corresponding change in the STL trend component of groundwater depth anomalies in the NCP. Both axes use logarithmic scales. Point colors indicate months, and labels such as “2014Q2” denote the year and calendar quarter. The red arrow indicates the leftward shifts observed during droughts. The dashed gray line indicates a stable trend. c Same as (a), but for Beijing: annual precipitation and groundwater depth anomalies in unconfined aquifers. d Same as (b), but for Beijing: precipitation-groundwater trend relationships based on STL decomposition.

    The coupling between precipitation and groundwater depth anomalies further highlights the impact of these interventions (Fig. 5b, d). A systematic leftward shift in precipitation-groundwater scatter plots indicates increasingly shallow groundwater conditions, even under similar rainfall conditions. These shifts are particularly pronounced during drought years (the red arrow in Fig. 5b), suggesting that the interventions have altered the groundwater balance and strengthened the system’s resilience. A similar pattern is observed in Beijing (Fig. 5d), where 2024 groundwater depths significantly improved compared to 2005. Although the extreme rainfall in 2021 temporarily accelerated groundwater recovery, its effect was short-lived, as soil moisture returned to baseline levels by early 2022 (Supplementary Fig. 3). In contrast, the continued groundwater rises in Beijing (2016–2020) and the ongoing NCP-wide recovery since 2022 underscore the effectiveness and durability of policy-led groundwater restoration efforts.

    MAR and reduced irrigation-related pumping are critical strategies for restoring depleted aquifers (Fig. 6a–c). For years, rivers in the NCP had dried up due to upstream reservoir interception and declining groundwater levels. Experimental river replenishment began in 2018 in the Fuyang, Hutuo, and Juma rivers. Since then, over 10 km3 of water from the SNWD project has been allocated to restore rivers across the NCP by 2024. Additional contributions came from Yellow River diversions and local reservoirs, benefiting rivers (e.g., the Yongding River) and lakes (e.g., the Baiyangdian Lake). These efforts have rejuvenated drying rivers, restored riparian ecosystems, and enhanced aquifer recharge. Wells near replenished rivers exhibited more rapid groundwater recovery rates (Fig. 6b), confirming the effectiveness of river-based MAR. Other MAR methods, including flood-restoring recharge ponds and injection wells targeting confined aquifers, were employed but at smaller scales. In parallel, changes in irrigation practices also contributed to partial recovery. The NCP’s dominant double cropping system (winter wheat and summer maize rotation) requires intensive spring irrigation, historically sustained by groundwater pumping. Between 2013 and 2018, the area under double cropping declined by ~10,000 km230. In rural areas between Beijing and Langfang, where the reduction was the greatest30, groundwater recovery began as early as 2013–2014 (Fig. 6c). Since 2018, further decline in double-cropped area has slowed, as diverted water has allowed local surface water to be redirected for irrigation30. In contrast, the southeastern NCP retained stable cropping patterns due to reliance on Yellow River diversions. Despite the cropping adjustments, regional food production in Beijing, Tianjin, and Hebei rose from ~28 million tons in 2005 to ~42 million tons in 2023 (Supplementary Fig. 4)33, aided by increased yield per unit area, helping to ensure local food security.

    Fig. 6: Engineering and policy approaches for reversing groundwater depletion.
    figure 6

    a Water diversion and river replenishment in the North China Plain (NCP). The green line represents the boundary of the NCP. Blue polygons represent lakes and reservoirs. Blue, orange, and dark red lines represent rivers, the central route of the South-to-North Water Diversion (SNWD-C), and the eastern route of the South-to-North Water Diversion (SNWD-E), respectively. b Groundwater depth in unconfined aquifers near replenished rivers. Green, purple, gray, and red lines correspond to four monitoring wells located between the Sha and the Hutuo rivers from 2018 to 2024. c Groundwater depth in unconfined aquifers in areas where double-cropped acreage declined substantially between 2013 and 2017. Green and purple lines represent two representative monitoring wells. d GRACE-derived total water storage anomalies (TWSA) in the NCP. The green line shows the average of the JPL and CSR mascon products; the shaded green area shows their spread. The thick blue line represents the trend (based on STL decomposition). e Annual groundwater balance in the NCP from 2005 to 2023. The x axis shows net groundwater abstraction (abstraction minus recharge) based on Hai River Water Resources Bulletins (km3). The y axis represents the annual change in the trend in groundwater depth (based on STL decomposition) in unconfined aquifers, with the dashed gray line indicating a stable trend. Sy_fit indicates the fitted specific yield derived from the slope of the balance-depth relationship.

    Groundwater depth recovery observed in monitoring wells is consistent with both satellite-based and water balance estimates (Fig. 6d, e). Interannual changes in groundwater depth in unconfined aquifers show a strong linear relationship (R2 = 0.87) with net water balance deficits, calculated as annual groundwater abstraction minus recharge from the Hai River Water Resources Bulletins (Fig. 6e). The fitted specific yield (Sy_fit) of 0.07 generally matches reported values of ~0.12 in the piedmont plains and ~0.04 in other regions of the NCP25, supporting the reliability of the water balance approach34 (see Methods). Satellite observations from GRACE and GRACE-FO show a recovery in total water storage anomalies (TWSA) beginning around 2020 (Fig. 6d), yet this rebound compensates for only about half of the ~49 km3 of total water storage depletion between 2005 and 2019. Based on a 3 m decline in groundwater level and the estimated Sy_fit, unconfined aquifer storage alone decreased by ~27 km3 during this period. Confined aquifers, characterized by much smaller storage coefficients (0.0004–0.004), contributed relatively little to the total depletion, indicating that the majority of groundwater loss occurred in unconfined systems25. Discrepancies between GRACE TWSA data and in-situ groundwater trends likely stem from variations in soil and surface water storage, uncertainties in specific yield and storage coefficients, or inherent limitations in GRACE resolution. A full attribution of these differences is beyond the scope of this study.

    Continue Reading

  • New EDR killer tool used by eight different ransomware groups – BleepingComputer

    1. New EDR killer tool used by eight different ransomware groups  BleepingComputer
    2. Shared secret: EDR killer in the kill chain  Sophos News
    3. Hackers Weaponizing Free Trials of EDR to Disable Existing EDR Protections  CyberSecurityNews
    4. Hackers Abuse EDR Free Trials to Bypass Endpoint Protection  gbhackers.com

    Continue Reading

  • Scientists grow mini brain in a lab

    Scientists grow mini brain in a lab



    Researchers have grown a new whole-brain organoid, complete with neural tissues and rudimentary blood vessels.

    It’s an advance that could usher in a new era of research into neuropsychiatric disorders such as autism.

    “We’ve made the next generation of brain organoids,” says lead author Annie Kathuria, an assistant professor in Johns Hopkins University’s biomedical engineering department who studies brain development and neuropsychiatric disorders.

    “Most brain organoids that you see in papers are one brain region, like the cortex or the hindbrain or midbrain. We’ve grown a rudimentary whole-brain organoid; we call it the multi-region brain organoid (MRBO).”

    The research in Advanced Science marks one of the first times scientists have been able to generate an organoid with tissues from each region of the brain connected and acting in concert. Having a human cell-based model of the brain will open possibilities for studying schizophrenia, autism, and other neurological diseases that affect the whole brain—work that typically is conducted in animal models.

    To generate a whole-brain organoid, Kathuria and members of her team first grew neural cells from the separate regions of the brain and rudimentary forms of blood vessels in separate lab dishes. The researchers then stuck the individual parts together with sticky proteins that act as a biological superglue and allowed the tissues to form connections. As the tissues began to grow together, they started producing electrical activity and responding as a network.

    The multi-region mini brain organoid retained a broad range of types of neuronal cells, with characteristics resembling a brain in a 40-day-old human fetus. Some 80% of the range of types of cells normally seen at the early stages of human brain development was equally expressed in the laboratory-crafted miniaturized brains.

    Much smaller compared to a real brain—weighing in at 6 million to 7 million neurons compared with tens of billions in adult brains—these organoids provide a unique platform on which to study whole-brain development.

    The researchers also saw the creation of an early blood-brain barrier formation, a layer of cells that surround the brain and control which molecules can pass through.

    “We need to study models with human cells if you want to understand neurodevelopmental disorders or neuropsychiatric disorders, but I can’t ask a person to let me take a peek at their brain just to study autism,” Kathuria says.

    “Whole-brain organoids let us watch disorders develop in real time, see if treatments work, and even tailor therapies to individual patients.”

    Using whole-brain organoids to test experimental drugs may also help improve the rate of clinical trial success, researchers says. Roughly 85% to 90% of drugs fail during Phase 1 clinical trials. For neuropsychiatric drugs, the fail rate is closer to 96%. This is because scientists predominantly study animal models during the early stages of drug development. Whole-brain organoids more closely resemble the natural development of a human brain and likely will make better test subjects.

    “Diseases such as schizophrenia, autism, and Alzheimer’s affect the whole brain, not just one part of the brain. If you can understand what goes wrong early in development, we may be able to find new targets for drug screening,” Kathuria says.

    “We can test new drugs or treatments on the organoids and determine whether they’re actually having an impact on the organoids.”

    Source: Johns Hopkins University

    Continue Reading

  • Epcoritamab Plus Rituximab and Lenalidomide Hits Both Primary End Points in R/R Follicular Lymphoma

    Epcoritamab Plus Rituximab and Lenalidomide Hits Both Primary End Points in R/R Follicular Lymphoma

    Blood Cells | Image credit:

    © Bipul Kumar – stock.adobe.com

    The combination of epcoritamab-bysp (Epkinly), rituximab (Rituxan), and lenalidomide (Revlimid) demonstrated significant improvements in overall response rate (ORR) and progression-free survival (PFS) compared with rituximab and lenalidomide in patients with relapsed/refractory follicular lymphoma, meeting the coprimary end points of the phase 3 EPCORE FL-1 (NCT05409066).1

    Data from a preplanned interim analysis of EPCORE FL-1 revealed that patients who received the triplet experienced a 79% reduction in the risk of death or disease progression compared with those treated with only rituximab and lenalidomide (HR, 0.21; P < .0001). Moreover, there was a significant benefit in terms of ORR in favor of the investigational arm (P <.0001).

    In July 2025, the FDA accepted the supplemental Biologics License Application (sBLA) of epcoritamab plus rituximab and lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma following at least 1 prior systemic therapy. The sBLA submission was based on prior findings from EPCORE FL-1. The FDA set a Prescription Drug User Fee Act target action date of November 30, 2025.

    “[Although] therapeutic options exist for patients with relapsed/refractory follicular lymphoma, response rates tend to decline and durability diminishes with each subsequent line of treatment, which can increase the risk of the disease transforming into aggressive large-cell lymphoma,” Jan van de Winkel, PhD, president and chief executive officer of Genmab, stated in a news release. “The results from this trial, and the decision from the FDA to accept the sBLA for priority review, demonstrate the potential of this epcoritamab combination therapy to reshape the treatment landscape and reinforces our shared commitment with AbbVie to advance epcoritamab as a potential core therapy across B-cell malignancies.”

    EPCORE FL-1 was an open-label study that evaluated epcoritamab plus rituximab and lenalidomide in adult patients with relapsed/refractory follicular lymphoma who received at least 1 prior systemic regimen containing an anti-CD20 monoclonal antibody plus chemotherapy.2 Additional inclusion criteria consisted of having an estimated creatine clearance of at least 50 mL/minute, at least 1 measurable lesion per CT scan or MRI, and an ECOG performance status of 0 to 2. Patients were also required to have stage II to IV disease without evidence of histologic transformation to an aggressive lymphoma and CD20-positive disease.

    Eligible patients were randomly assigned 1:1 to receive subcutaneous epcoritamab at 48 mg for up to twelve 28-day cycles in combination with intravenous rituximab and oral lenalidomide or rituximab and lenalidomide alone.2,3 Patients in both arms received rituximab at 375 mg/m2 for up to 5 cycles and lenalidomide at 20 mg for up to 12 cycles.2

    The coprimary end points were best overall response (BOR) rate and PFS. Secondary end points included complete response (CR) rate, overall survival, minimal residual disease negativity rate, change in Functional Assessment of Cancer Therapy–Lymphoma scale, investigator-assessed PFS, investigator-assessed BOR rate, investigator-assessed CR rate, duration of CR, time to disease progression, and event-free survival.

    In terms of safety, findings from the interim analysis showed that the safety profile of epcoritamab plus rituximab and lenalidomide in patients with relapsed/refractory follicular lymphoma was consistent with the known safety profiles of the individual regimens.1 Notably, no new safety signals were reported.

    In June 2024, the FDA approved epcoritamab monotherapy for the treatment of patients with relapsed/refractory follicular lymphoma after at least 2 lines of systemic therapy.4 The approval was supported by findings from the phase 1/2 EPCORE NHL-1 trial (Study GCT3013-01; NCT03625037), which demonstrated that patients who received the agent (n = 127) achieved an ORR of 82% (95% CI, 74.1%-88.2%).

    The FDA has also granted breakthrough therapy designation to the combination of epcoritamab plus rituximab and lenalidomide for the treatment of adult patients with relapsed/refractory lymphoma who received at least 1 prior line of treatment.1

    Additional data from the interim analysis of EPCORE FL-1 will be submitted for presentation at the 2025 ASH Annual Meeting and Exposition, according to Genmab.The findings will also serve as the basis for global regulatory submissions.

    References

    1. Genmab announces phase 3 EPCORE FL-1 clinical trial met dual primary endpoints in patients with relapsed/refractory (R/R) follicular lymphoma (FL). News release. Genmab. August 7, 2025. Accessed August 7, 2025. https://ir.genmab.com/news-releases/news-release-details/genmab-announces-phase-3-epcorer-fl-1-clinical-trial-met-dual
    2. Study of subcutaneous epcoritamab in combination with intravenous rituximab and oral lenalidomide (R2) to assess adverse events and change in disease activity in adult participants with follicular lymphoma (EPCORE FL-1). ClinicalTrials.gov. Updated July 28, 2025. Accessed August 7, 2025. https://clinicaltrials.gov/study/NCT05409066
    3. Falchi L, Morschhauser F, Linton K, et al. EPCORE FL-1: phase 3 trial of subcutaneous epcoritamab with rituximab and lenalidomide (R 2) Vs R 2 alone in patients with relapsed or refractory follicular lymphoma. Blood. 2023;142(suppl 1):3053. doi:10.1182/blood-2023-180092
    4. FDA grants accelerated approval to epcoritamab-bysp for relapsed or refractory follicular lymphoma. FDA. June 26, 2024. Accessed August 7, 2025. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-epcoritamab-bysp-relapsed-or-refractory-follicular-lymphoma

    Continue Reading